GlassScriptPhysician profile
Imran Nazeer
NPI 1477582039
$3,893.30
in general payments reported to CMS, 2019-2025
32 companies · $731 in 2025
The $731 reported for 2025 was more than what 84% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $669 · 2020: $148 · 2021: $59.95 · 2022: $576 · 2023: $710 · 2024: $1,000 · 2025: $731.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,439 · Education: $2.05.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,438.68 |
| Education | $2.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $662.08 | 2019-2025 | Farxiga, Lokelma |
| Ani Pharmaceuticals, INC. | $439.03 | 2024-2025 | Purified Cortrophin Gel |
| Bayer Healthcare Pharmaceuticals INC. | $360.89 | 2022-2025 | |
| Amgen INC. | $279.41 | 2019-2025 | Tavneos, Uplizna, Krystexxa |
| Calliditas Therapeutics US INC. | $234.40 | 2022-2025 | Tarpeyo |
| Vifor Pharma, INC. | $212.45 | 2019-2025 | Veltassa |
| Novartis Pharmaceuticals Corporation | $200.38 | 2024-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $172.45 | 2023-2025 | Jardiance |
| Janssen Biotech, INC. | $167.98 | 2019-2021 | |
| Aurinia Pharma U.S., INC. | $119.02 | 2022-2023 | Lupkynis |
| Pfizer INC. | $113.85 | 2023 | |
| Mallinckrodt Hospital Products INC. | $104.80 | 2020-2025 | Acthar |
| Mallinckrodt Enterprises LLC | $99.29 | 2019 | |
| Ardelyx, INC. | $92.69 | 2024-2025 | Ibsrela |
| Radius Health, INC. | $79.67 | 2019-2024 | Tymlos |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shield Therapeutics INC | $78.93 | 2024 | |
| Travere Therapeutics, INC. | $73.77 | 2021-2025 | Filspari |
| Glaxosmithkline, LLC. | $68.19 | 2021-2024 | Jesduvroq |
| Novo Nordisk INC | $47.19 | 2024-2025 | Ozempic, Rybelsus |
| Otsuka America Pharmaceutical, INC. | $45.02 | 2019 | |
| Horizon Therapeutics Plc | $39.25 | 2019 | |
| Boston Scientific Corporation | $35.51 | 2025 | Watchman Flx |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $31.09 | 2020 | |
| Akebia Therapeutics INC | $27.91 | 2022 | |
| Cormedix INC. | $22.40 | 2024 | Defencath |
| Merck Sharp & Dohme LLC | $20.88 | 2023 | Verquvo |
| Sandoz INC. | $20.77 | 2023 | Hyrimoz |
| Philips North America LLC | $16.13 | 2019 | |
| Medtronic, INC. | $15.91 | 2023 | Minimed 770g |
| Nxstage Medical, INC. | $11.96 | 2019 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Imran Nazeer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.